Sepracor Sees Reward In Lunesta Promotion Push
This article was originally published in The Pink Sheet Daily
Sepracor credits its intensive marketing sales and education programs as the key to new prescription growth in the third quarter despite the recent entry of two competing sleep aids.
You may also be interested in...
Sepracor's Lunesta (eszopiclone) "product and use" ad campaign will "be very visible going forward," the company said during its April 25 earnings call
Two of the leading medical journals are offering opposing viewpoints on mandatory human papilloma virus vaccination, with experts contributing perspective pieces that directly reflect the larger political and social division over the issue
FDA's "not approvable" action on Merck's Vioxx follow-on Arcoxia for the treatment of symptoms of osteoarthritis could be indicative of a conservative regulatory climate at the agency